TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.
We envision a world where no one dies of tuberculosis. However, this cannot be achieved without improved, faster-acting, and affordable tuberculosis drug regimens that are available to all who need them. These new cures can bring renewed health, hope, and prosperity to millions. Since our inception in 2000, TB Alliance has led the global search for and development of new TB regimens, catalyzing the field and convening cross-sector partnerships to forge the progress that is urgently needed for better TB treatments.
TB Alliance is a not-for-profit product development partnership (PDP), uniquely positioned to leverage a global network of public and private partners to most efficiently advance TB drug development. A PDP builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. PDPs retain direct management oversight of their projects, though much of the laboratory and clinical work is done though external research facilities and contractors. We combine the research and development expertise of our staff with the skills and resources of our partners to harness the most promising science wherever it may exist around the world. This model minimizes costs, including overhead and investments in infrastructure, while optimizing scientific capability to speed new TB drug development. Our business model and diverse partnerships allow TB Alliance to leverage additional partner services for every dollar invested in the TB Alliance. In 2019, TB Alliance became the first not-for-profit organization to develop and register an anti-TB drug.
Making an Impact
TB Alliance was conceived at a February 2000 meeting in Cape Town, South Africa, where 120 representatives from academia, industry, major agencies, non-governmental organizations, and donors gathered to discuss the need for new TB treatments. At the time, there were no TB drugs in clinical development and, therefore, little hope for better cures. The resulting "Declaration of Cape Town" provided a road map for TB drug development, outlining the need for the creation of TB Alliance. Since then, TB Alliance and its diverse and extensive network of partners have gone on to transform the landscape of TB drug development. Accomplishments include developing the first-ever FDA-approved treatment for highly drug-resistant TB, development of child-friendly treatments for drug-sensitive TB, building a robust portfolio of new TB drug candidates, and changing the way TB research is conducted.